NCT05453006 2025-07-10
Isbaar
University of Minnesota
Phase NA Completed
Clinical Trials
27 trialsNCT04772469 2025-04-29
Self-Test Strategies and Linkage Incentives to Improve ART and PrEP Uptake in Men
University of California, San Francisco
Phase NA Completed
NCT04053283 2025-03-24
STAR
Akamis Bio
Phase 1 Completed
NCT03487549 2024-11-27
COVE-1
Verrica Pharmaceuticals Inc.
Phase 2 Completed
NCT03981822 2024-11-27
CARE-1
Verrica Pharmaceuticals Inc.
Phase 2 Completed
NCT03463694 2024-05-17
ELVIS Kids
University of Edinburgh
Phase NA Completed
NCT04746872 2024-02-12
Alinity m HR HPV Specimen Collection Study From Women Undergoing Routine Cervical Cancer Screening
Abbott Molecular
Completed
NCT02457845 2024-01-19
HSV G207 Alone or With a Single Radiation Dose in Children With Progressive or Recurrent Supratentorial Brain Tumors
University of Alabama at Birmingham
Phase 1 Completed
NCT03408587 2023-05-06
CLEVER
Viralytics
Phase 1 Completed
NCT02759588 2023-01-05
GL-ONC1 Oncolytic Immunotherapy in Patients With Recurrent or Refractory Ovarian Cancer
Genelux Corporation
Phase 1/2 Completed
NCT01970254 2022-08-15
Widespread vs. Selective Screening for Hepatitis B Infection Prior to Chemotherapy
M.D. Anderson Cancer Center
Completed
NCT01567813 2022-07-22
Post-Licensure Study of the Safety of GARDASILâ„¢ in Males (V501-070)
Merck Sharp & Dohme LLC
Completed
NCT03852511 2022-06-24
FORTITUDE
Akamis Bio
Phase 1 Completed
NCT02482428 2021-01-05
Efficacy and Tolerability of Topical LFX453 for External Genital Warts
Novartis
Phase 2 Completed
NCT02227641 2020-12-14
Preventative/Preemptive Adoptive Transfer of Peptide Stimulated CMV/EBV Specific T-cells in Patients After Allogeneic Stem Cell Transplantation
University of Erlangen-Nürnberg Medical School
Phase 1/2 Completed
NCT02868242 2020-03-02
Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed Dose Combination in the Treatment of Hepatitis C Virus (HCV) Infection in Pediatric Participants Undergoing Cancer Chemotherapy
Gilead Sciences
Phase 2 Completed
NCT00423046 2020-01-02
Immunogenicity of GlaxoSmithKline Biological's Human Papillomavirus (HPV) Vaccine (580299) Versus Merck's Gardasil® in Healthy Females 18-45 Years of Age
GlaxoSmithKline
Phase 3 Completed
NCT01570283 2019-05-30
ARMS
AlloVir
Phase 1/2 Completed
NCT00492544 2018-09-04
Immunogenicity and Safety of GSK Biologicals' HPV Vaccine 580299 in Healthy Japanese Females 10-15 Years of Age
GlaxoSmithKline
Phase 3 Completed
NCT00541970 2018-08-17
Partially Blind Study to Evaluate Immunogenicity & Safety of GSK Bio's HPV Vaccine 580299 in Healthy Women Aged 9-25 Yrs
GlaxoSmithKline
Phase 1 Completed
NCT02724254 2018-07-20
A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of Twice Daily Topical Applications of AP611074 5% Gel for up to 16 Weeks in Condyloma Patients
Vaxart
Phase 2 Completed
NCT00341211 2017-07-02
Specimens From Normal Controls
National Institutes of Health Clinical Center (CC)
Completed
NCT01804829 2017-03-15
Civacir® Polyclonal Immune Globulin (IgG) to Prevent Hepatitis C Virus (HCV) Recurrence in Liver Transplant Patients.
Biotest Pharmaceuticals Corporation
Phase 3 Completed
NCT01598779 2015-12-21
Human Papillomavirus (HPV) Types Present in External Genital Warts (EGW) in the Argentinean Population
University of Buenos Aires
Completed
NCT01070797 2014-09-04
VIRAGE
Baylor College of Medicine
Phase 1 Completed
NCT00925288 2012-10-11
Girasol
Johns Hopkins Bloomberg School of Public Health
Phase 4 Completed
NCT01031719 2012-09-13
Clinical Trial to Compare the Immunogenicity, Safety, and Tolerability of an Adjuvanted A(H1N1) Influenza Vaccine Versus Non-Adjuvanted A(H1N1) Influenza Vaccines in Patients With Invasive Solid Tumors
Chiltern Pesquisa Clinica Ltda
Phase 3 Completed